MedTrace Logo

VIDAS Nephroclear (NCL) CCL14 - Sample Stability

NCT05271617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-09-11

No results posted yet for this study

Summary

This VIDAS® NEPHROCLEAR™ CCL14 (VIDAS® NCL™ CCL14) Sample Stability clinical trial is a multicenter, prospective, and qualitative study. The main study objective is to determine sample stability conditions for the VIDAS® NEPHROCLEAR™ CCL14 Test. This test is intended to be used in conjunction with clinical evaluation in ICU patients with moderate to severe (stage 2 or 3) acute kidney injury (AKI) as an aid in the risk assessment for developing persistent severe AKI (stage 3 AKI lasting ≥ 72 hours) within 48 hours of patient assessment. The VIDAS® NEPHROCLEAR™ CCL14 Test is intended to be used in patients 21 years of age or older.

Conditions

Interventions

DIAGNOSTIC_TEST

VIDAS® NEPHROCLEAR™ CCL14

Measurement of CCL14 in sample aliquots after being subjected to different testing conditions

Sponsors & Collaborators

  • BioMérieux

    lead INDUSTRY

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05271617 on ClinicalTrials.gov